z-logo
Premium
Pharmacokinetics (PK) of multiple oral doses of desloratadine (DCL) and fexofenadine (FEX) in a population of healthy adults identified phenotypically as desloratadine slow metabolizers (DSMS)
Author(s) -
Kraft W.,
Blum R. A.,
Frick G. S.,
Vitow C.,
Stewart J. A.,
Kovacs S. J.
Publication year - 2005
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2004.12.066
Subject(s) - desloratadine , pharmacokinetics , fexofenadine , crossover study , dosing , population , medicine , chemistry , pharmacology , placebo , alternative medicine , environmental health , pathology
Purpose To characterize the PK of DCL and FEX in adults identified as DSMs. Methods This was a randomized, double blind, crossover study with a 21‐day washout between treatments. DSM subjects received DCL 5 mg or FEX HCI 180 mg QD for 7 days during each treatment period. Serial blood sampling was performed on days 1 and 7, trough samples were collected on Days 5 and 6 and samples were collected 48, 72, 96, 120, and 144 hrs after the Day 7 dose. Plasma was assayed for DCL, 3‐OH‐DCL, and FEX by LC/MS/MS. Results 18 subjects (15 M, 3 F) with a mean (SD) age of 32.2 (±7.33) years and BMI of 27.0 (±3.7) kg/m 2 were enrolled. Exposure to DCL increased 5‐fold on Day 7. Relatively low concentrations of 3‐OH‐DCL were quantifiable more often on Day 7 than Day 1. The disposition of FEX was consistent with previous reports in subjects and patients, with no significant accumulation after 7 days of dosing. Mean (SD) half‐lives of 112±56.2 and 17.2±7.3 hrs were estimated for DCL and FEX, respectively, compared with 27 hrs reported for DCL normal metabolizers. Conclusions In DSMs substantial accumulation of DCL was observed; however, steady‐state was not reached by Day 7, which suggests continued accumulation with treatment beyond 7 days. There was no apparent alteration of FEX PK in DSMs. The safety of prolonged increased DCL exposure in a variety of clinical settings has not been established. The metabolic pathway responsible for the DSM phenotype remains unknown. (see Table) Clinical Pharmacology & Therapeutics (2005) 77 , P45–P45; doi: 10.1016/j.clpt.2004.12.066DCL Day 1 DCL Day 7 FEX Day 1 FEX Day 7AUC (0–24) (ng · hr/mL) Mean ± SD 40.29 ± 12.62 196.80 ± 53.76 2096 ± 1002 2357 ± 909 C max (ng/mL) Mean ± SD 2.48 ± 0.95 9.84 ± 2.67 367 ± 222 384 ± 180 T max (hrs) Median (Min, Max) 7 (2.5, 12) 7 (6, 12) 2.5 (1, 6) 1.5 (1, 6) C 24h (ng/mL) Mean ± SD 1.62 ± 0.48 7.57 ± 2.26 11.0 ± 3.1 18.4 ± 8.5

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom